Fotemustine is a chemotherapy medication used to treat certain types of cancer, including Hodgkin’s lymphoma, malignant brain tumors, and certain types of melanoma. It works by interfering with the growth of cancer cells and preventing them from spreading. Side effects may include nausea, vomiting, loss of appetite, and hair loss.
Fotemustine is a nitrosourea alkylating agent medication used in the treatment of metastatic melanoma, a type of skin cancer that has spread to other parts of the body. It is available in Europe but has not been approved by the U.S. Food and Drug Administration (FDA) .
Studies have shown that fotemustine produces improved response rates compared to dacarbazine (DTIC), another chemotherapy drug used for metastatic melanoma, but it does not increase survival. It also has a higher prevalence of side effects, with neutropenia (low white blood cell count) and thrombocytopenia (low blood platelet count) being the most common.
Here are some additional details about fotemustine:
- Mechanism of action: Fotemustine works by damaging the DNA of cancer cells, which prevents them from growing and dividing.
- Dosage and administration: Fotemustine is given as an intravenous (IV) infusion over 60 minutes. The dose is typically based on the patient's body size and weight.
- Side effects: As mentioned earlier, the most common side effects of fotemustine are neutropenia and thrombocytopenia. Other potential side effects include nausea, vomiting, fatigue, hair loss, and loss of appetite.
- Contraindications: Fotemustine is not recommended for people with severe bone marrow suppression or a weakened immune system.
If you are considering fotemustine for the treatment of metastatic melanoma, it is important to discuss the risks and benefits of this medication with your doctor.